Fact checked byRobert Stott

Read more

June 11, 2024
2 min read
Save

FDA approves Ipsen’s Iqirvo ‘to address unmet need’ in primary biliary cholangitis

Fact checked byRobert Stott
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

The FDA granted accelerated approval to Ipsen Pharma’s Iqirvo 80 mg, a first-in-class oral, once-daily peroxisome proliferator-activated receptor agonist for the treatment of primary biliary cholangitis, according to a company release.

Perspective from Dian-Jung Chiang, MD, MPH

Originally given breakthrough therapy designation in 2019, Iqirvo (elafibranor, Ipsen/Genfit), is now indicated as second-line therapy in combination with ursodeoxycholic acid (UDCA) for adult patients with inadequate response to UDCA, or as monotherapy in those who are intolerant to UDCA.

Image: Healio
The FDA granted accelerated approval to Ipsen Pharma’s Iqirvo 80 mg, a first-in-class oral, once-daily peroxisome proliferator-activated receptor agonist for the treatment of primary biliary cholangitis.

The FDA based its decision on Iqirvo’s reduction in alkaline phosphatase levels, which were “sustained through week 52” with rapid response “seen as early as week 4” in the randomized double-blind, placebo-controlled, phase 3 ELATIVE trial, intended to assess the efficacy and safety of once-daily Iqirvo 80 mg plus UDCA (n=108) vs. placebo plus UDCA (n=53).

“Data from the pivotal phase 3 ELATIVE clinical trial demonstrated that Iqirvo is an effective second-line treatment for patients with PBC with favorable benefit and risk data,” Kris Kowdley, MD, director at Liver Institute Northwest in Washington and a primary investigator on the ELATIVE study, said in an Ipsen press release. “The approval of Iqirvo will allow health care providers in the U.S. to address an unmet need with the potential to significantly reduce ALP levels for our patients with PBC.”

According to the 52-week results, 13 times more patients treated with Iqirvo plus UDCA achieved the composite primary endpoint of biochemical response compared with placebo plus UDCA (51% vs. 4%), with a treatment difference of 47%. Further, the secondary endpoint of ALP normalization was achieved in 15% of patients treated with Iqirvo vs. none who received placebo.

During the recent EASL Congress, researchers reported that Iqirvo’s biochemical response was sustained through week 78 and may potentially reduce pruritus and improve itch-related quality of life in those with PBC.

“For a significant number of people living with PBC, available treatments do not control the condition and may exacerbate symptoms of PBC. Left unmanaged, PBC can progress, leading to liver failure and, in some cases, the need for a liver transplant,” Christelle Huguet, executive vice president and head of research and development at Ipsen, said. “Iqirvo demonstrated statistically significant improvements in biochemical response compared to UDCA alone. Iqirvo is therefore a much-needed treatment option and the first new medicine for PBC in nearly a decade.”

Data from the ELATIVE trial has yet to show improvement in survival or prevention of liver decompensation events. Therefore, continued approval “may be contingent upon verification and description of clinical benefit in confirmatory trial(s),” the release stated.

Common adverse reactions were reported in at least 10% of patients, including weight gain, abdominal pain, diarrhea, nausea and vomiting. In addition, some patients experienced myalgia, myopathy and rhabdomyolysis, fractures, adverse effects on fetal and newborn development, drug-induced liver injury, hypersensitivity reactions or biliary obstruction.

Of note, Iqirvo is not recommended for patients who have or develop decompensated cirrhosis, the release said.

The company noted it has submitted requests seeking authorization of Iqirvo for PBC to the European Medicines Agency and the UK Medicines and Healthcare products Regulatory Agency, with final regulatory decisions expected in the second half of 2024.